Challenges in neoantigen-directed therapeutics

Lien Lybaert, Steve Lefever, Bruno Fant, Evelien Smits, Bruno De Geest, Karine Breckpot, Luc Dirix, Steven A Feldman, Wim van Criekinge, Kris Thielemans, Sjoerd H van der Burg, Patrick A Ott, Cedric Bogaert

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
64 Downloads (Pure)


A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a promising strategy that aims at targeting the host's immune response against tumor-specific antigens, thereby eradicating cancer cells. Initial forays have been made in clinical environments utilizing vaccines and adoptive cell therapy; however, many challenges lie ahead. We provide an in-depth overview of the current state of the field with an emphasis on in silico neoantigen discovery and the clinical aspects that need to be addressed to unlock the full potential of this therapy.

Original languageEnglish
Pages (from-to)15-40
Number of pages26
JournalCancer Cell
Issue number1
Early online date7 Nov 2022
Publication statusPublished - 9 Jan 2023


Dive into the research topics of 'Challenges in neoantigen-directed therapeutics'. Together they form a unique fingerprint.

Cite this